HER2+ 유방암

211개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved211 programs
AntibodyLimited DatastaleRochePreclinical

trastuzumab (Herceptin, Herceptin (trastuzumab))

Breast Neoplasms · Breast Neoplasms

#BreastNeoplasms#Antibody#Preclinical#monoclonal-antibody#Roche
Trials 1Status Discontinued
CGTLimited DatastaleThe Methodist Hospital Research…Phase 2

IL-12 gene therapy (IL-12 gene therapy)

Triple Negative Breast Cancer; Anthracycline-refractory TNBC · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
ADCLimited DatastaleDaiichi SankyoPhase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Megestrol Acetate + Trastuzumab Deruxtecan)

Advanced/Metastatic Breast Cancer; HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer · HER2

#HER2#ADC#Phase3#antibody-drug-conjugate#Advanced+3
Trials 1Status Recruiting
AntibodyLimited DatastaleNeoTX Therapeutics Ltd.Phase 1

durvalumab (Imfinzi, Naptumomab estafenatox and durvalumab)

ER+ Breast Cancer; Ovarian Cancer · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#ER+BreastCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 2

pembrolizumab (Keytruda, Neoadjuvant Pembrolizumab)

Breast Cancer; Triple Negative Breast Cancer (TNBC) · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Neoadjuvant chemotherapy combined with Toripalimab (Neoadjuvant chemotherapy combined with Toripalimab)

TNBC, Triple Negative Breast Cancer · TNBC, Triple Negative Breast Cancer

#TNBCTripleNegativeBreastCancer#Antibody#Phase2#monoclonal-antibody#TNBC+2
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab)

HR Positive/HER2 Low Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#HRPositive+2
Trials 1Status Recruiting
ADCLimited DatastaleShengjing HospitalPhase 2

Next-generation Site-specific human epidermal growth factor receptor 2 (HER2, Next-generation Site-specific human epidermal growth factor receptor 2, Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788))

Breast Neoplasms · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+1
Trials 1Status Recruiting
ADCLimited DatastaleGilead SciencesPreclinical

ADC (Non-Investigational Antibody-Drug Conjugates, Non-Investigational Antibody-Drug Conjugates (ADC))

HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma · HER2

#HER2#ADC#Preclinical#antibody-drug-conjugate#HER2-negativeBreastCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 1

durvalumab (Imfinzi, Obinutuzumab, naptumomab estafenatox and durvalumab)

ER+ Breast Cancer; Ovarian Cancer · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#ER+BreastCancer+2
Trials 1Status Recruiting
CGTLimited DatastaleMayo ClinicPhase 1

Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein (Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein)

Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma · Anatomic Stage IV Breast Cancer AJCC v8

#AnatomicStageIVBreastCancerAJCCv#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleImugene LimitedPhase 1

Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody (Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastalePoseida Therapeutics, Inc.Phase 1

P-MUC1C-ALLO1 CAR-T cells (P-MUC1C-ALLO1 CAR-T cells)

Breast Cancer; Ovarian Cancer · Breast Cancer

#BreastCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleThe Netherlands Cancer InstitutePhase 3

PTC+Pertuzumab (PTC+Pertuzumab)

Breast Cancer; HER2 Positive · HER2

#HER2#Antibody#Phase3#monoclonal-antibody#BreastCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleShanghai JMT-Bio Inc.Phase 2

Pembolizumab (Pembolizumab)

HER2-positive Gastric Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#HER2-positiveGastricCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 3

ZRC-3277 (Pertuzumab, Pertuzumab (ZRC-3277))

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleRochePreclinical

neoadjuvant (Pertuzumab, Pertuzumab (neoadjuvant))

HER2-positive Breast Cancer; Neoplasms · HER2

#HER2#Antibody#Preclinical#monoclonal-antibody#HER2-positiveBreastCancer+2
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Pertuzumab + trastuzumab + metronomic chemotherapy)

Elderly Metastatic Breast Cancer Population · Elderly Metastatic Breast Cancer Populat

#ElderlyMetastaticBreastCancerPop#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf)

Breast Cancer; Breast Neoplasm · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastCancer+2
Trials 1Status Recruiting
AntibodyLimited DatastaleEmory UniversityPhase 2

trastuzumab (Herceptin, Pre operativeTrastuzumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Emory
Trials 1Status Active

8 / 11 pages

← PreviousNext →